Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2b/interferon gamma - Heber Biotech

Drug Profile

Interferon alpha-2b/interferon gamma - Heber Biotech

Alternative Names: CIGB-128; CIGB-128-A; HeberFERON; HeberPAG; Interferon-alpha-2b/interferon-gamma; Interferon-gamma/interferon-alpha-2b

Latest Information Update: 27 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Basal cell cancer; COVID 2019 infections
  • No development reported Brain cancer; Mycosis fungoides

Most Recent Events

  • 27 Sep 2022 Phase-II development in COVID-2019 infections is ongoing in Cuba (SC) (RPCEC00000307)
  • 10 Apr 2020 Phase-II clinical trials in COVID-2019 infections in Cuba (SC) (RPCEC00000307)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Mycosis-fungoides in Cuba (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top